α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen–Expressing Human Colon Cancer Xenografts

Pretargeted radioimmunotherapy (PRIT) with the β-emitting radionuclide (177)Lu is an attractive approach to treat carcinoembryonic antigen (CEA)–expressing tumors. The therapeutic efficacy of PRIT might be improved using α-emitting radionuclides such as (213)Bi. Herein, we report and compare the tum...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Nucl Med
Main Authors: Heskamp, Sandra, Hernandez, Reinier, Molkenboer-Kuenen, Janneke D.M., Essler, Markus, Bruchertseifer, Frank, Morgenstern, Alfred, Steenbergen, Erik J., Cai, Weibo, Seidl, Christof, McBride, William J., Goldenberg, David M., Boerman, Otto C.
Formato: Artigo
Idioma:Inglês
Publicado em: Society of Nuclear Medicine 2017
Assuntos:
Theranostics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5450366/
https://ncbi.nlm.nih.gov/pubmed/28232604
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.116.187021
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados